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ABSTRACT:
Haem oxygenase-1 (HO-1) is increasingly regarded as a pro-tumoral target in the 
treatment of human cancers. Currently, little is known about HO-1 and its role 
in human acute myeloid leukaemia (AML) to regulate apoptosis in response to 
chemotherapy. Recently, we showed that HO-1 protects AML samples from tumour 
necrosis  factor-α  (TNF)-induced  apoptosis  -  it  being  regulated  by  transcription 
factors Nrf2, NF-ĸB and AP-1. This study aims to analyse the role of HO-1 in regulating 
apoptosis in AML cells in response to two front-line chemotherapeutic agents 
used for AML, cytarabine and daunorubicin. Here we show that HO-1 expression 
in AML samples was increased in response to both cytarabine and daunorubicin 
treatment, and micro RNA (miRNA) silenced HO-1 expression in combination 
with either daunorubicin or cytarabine induced a greater apoptotic responses in 
AML cells. Moreover, we showed that both daunorubicin and cytarabine induced 
reactive oxygen species (ROS) accumulation to induce apoptosis in AML. However, 
ROS-dependent induction of HO-1 was limiting the apoptotic response that is seen 
in  AML  towards  cytarabine  and  daunorubicin  treatment.  These  findings  suggest 
concurrent inhibition of HO-1 expression in conjunction with chemotherapeutic 
treatment would improve the number of cases who reach complete remission.
INTRODUCTION
Acute myeloid leukaemia (AML) is a malignancy 
of haemopoietic progenitor cells [1] and accounts for 
approximately 1% of all cancer deaths. At present the 
standard induction treatment for younger fitter patients 
consists of the antimetabolite cytarabine plus the 
anthracycline antibiotic daunorubicin [2, 3]. Depending 
on clinicopathological characteristics, patients who go 
into remission would commonly receive consolidation 
therapy with either high dose cytarabine or allogeneic 
stem cell transplant . Despite these intensive treatment 
strategies,  significant  numbers  of  patients  relapse  and 
only approximately 50% of younger fitter patients can be 
cured. The treatment outcomes are dependent on a variety 
of clinical and biological factors including cytogenetics, 
age and drug-resistance [2, 4-7]. 
A number of mechanisms have been suggested to 
contribute to drug-resistance in AML. These include, 
the targeted cells fail to undergo apoptosis in response 
to the chemotherapy agent, drugs failing to reach their 
intracellular targets or the removal by the ABC membrane 
transporter protein, P-glycoprotein (Pgp). Pgp is a efflux 
transporter, present within the cell’s plasma membrane, 
and its expression in AML has been reported to be 
relatively low, however an increase in its expression after 
drug treatment and also at the point of relapse, have been 
reported [8]. Moreover, Galmarini et al have shown that 
high levels of 5’-nucleotidase, which is involved in DNA 
repair and membrane transport, is related to the poor 
prognosis of AML patients [9]. These studies suggest 
that AML cells evolve to regulate pathways that provide 
protection against toxic chemotherapeutic agents. 
Recently, we reported that haem oxygenase-1 (HO-Oncotarget 2011; 2:  658 - 668 659 www.impactjournals.com/oncotarget
1) has an important function in protecting human AML 
cells from TNF-induced apoptosis [10]. To date, three 
isoforms of haem oxygenase have been identified, HO-1, 
HO-2 and HO-3 [11]. HO-1, which is the most intriguing 
in terms of providing protection against cellular stresses, 
regulates cellular haem levels, and converts intracellular 
haem into carbon monoxide, free iron and biliverdin [11]. 
Biliverdin is further reduced into the potent antioxidant 
bilirubin [12, 13]  by biliverdin reductase [14].  This 
metabolite possesses cytoprotective properties including 
anti-inflammatory, anti-oxidative and anti-apoptosis [15, 
16]. HO-2 is constitutively expressed and HO-3 is not 
catalytically active and thought to be involved in oxygen-
sensing. HO-1 belongs to the heat shock protein family 
(Hsp-32), thus its expression is triggered by a variety 
of stress-inducing stimuli including, UV irradiation, 
hyperthermia,  inflammatory  cytokines,  bacterial 
endotoxins and heavy metals [17-21]. The regulation of 
HO-1 is under the control of signalling components [22, 
23] and many transcription factors including nuclear 
factor-κB  (NF-κB),  NF-E2-related  factor  2  (Nrf2)  and 
activator protein-1 (AP-1)[24, 25].
Figure 1: AML cell resistance to cytarabine and daunorubicin. (A) AML cells were treated with two doses of cytarabine (0.5 µM 
and 1 µM) and two doses of daunorubicin (0.2 µM and 0.5 µM) for 24 hours. Viable cell numbers were then devised using PI and annexin 
V staining followed by flow cytometry.  Values indicate mean ± SD from three separate independent experiments. (B) U937 and THP-1 
cells were treated with either cytarabine 0.5 µM, daunorubicin 0.2 µM or a combination of cytarabine 0.5 µM and daunorubicin 0.2 µM 
for 24 hours. Samples were stained with annexin V and PI. Flow cytometry analysis was used to determine the percentage of viable cells 
present within the sample population. 
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Number  Age  Gender WHO diagnosis  Cytogenetics
% 
Blasts 
Previous 
treatment 
AML8  40  male 
Acute promyelocytic
leukaemia with 
t(15;17)(q22:q12) PML-
RARA 
t(15;17)  95* 
1999 DAT,DAT 
MACE,MiDAC 
[29]
AML9  49  male  AML with maturation  normal  80  nil 
AML10  84  male 
Acute monoblastic and 
monocytic leukaemia 
not available  nil 
AML11  46  female  AML with maturation  +4,+8, t(9;22)  70  nil 
AML12  78  male 
AML with myelodysplasia 
related changes 
not available  85  nil 
AML13  27  male 
AML with t(8;21)(q22;q22) 
RUNX1-RUNX1T1 
t(8;21)  nil 
AML14  28  female 
Acute myelomonocytic 
leukaemia 
normal  nil 
AML16  66  female 
therapy related myeloid 
neoplasm 
complex  85 
1999 DAT,DAT 
MACE,MiDAC 
[29]
AML18  77  male 
AML with myelodysplasia 
related changes 
complex  95  nil 
AML19  31  female 
AML with minimal 
differentiation 
normal  nil 
AML20  40  male 
Acute monoblastic and 
monocytic leukaemia 
constitutional XYY 
only 
90%  nil 
Table 1: Characteristics of study patient samples.  AML disease characteristics including WHO diagnosis and cytogenetics.   
Percent blast denotes % of AML blasts after purification using density gradient (* denotes % of blasts and promyelocytes).  Previous 
treatments are as outlined [29].  Abbreviations used: AML, Acute myeloid leukaemia; WHO, world health organisation.Oncotarget 2011; 2:  658 - 668 661 www.impactjournals.com/oncotarget
Furthermore we have recently we showed that HO-1 
is in fact down-regulated in AML by their constitutively 
active NF-κB activity present, and that inhibiting NF-κB 
brings HO-1 levels back to more normal levels, providing 
further secondary protection for AML cells against NF-κB 
inhibition. Here were undertaken to investigate the role 
of HO-1 in regulating cytoprotective responses to two 
common front-line chemotherapy agents, cytarabine and 
daunorubicin, which are currently widely used in treating 
patients presenting with AML.
Figure 2: Cytarabine and daunorubicin induce HO-1 expression in AML cells.  (A) AML cells were treated with cytarabine 
(0.5 µM or 1 µM) and daunorubicin (0.2 µM or 0.5 µM) for 24 hours. RNA was extracted from each sample and HO-1 mRNA was measured 
using real-time PCR. (B) U937 and THP-1 cells were treated with either cytarabine 0.5 µM, daunorubicin 0.2 µM or a combination of both 
cytarabine 0.5 µM and daunorubicin 0.2 µM for 24 hours. RNA was extracted from each sample and HO-1 expression was measured using 
real-time PCR. (C) U937 and THP-1 cells were treated with either cytarabine (0.5 µM or 1 µM) or daunorubicin (0.2 µM or 0.5 µM) for 
24 hours. Whole cell protein extracts were collected and separated via SDS-PAGE and examined using Western immunoblotting analysis. 
HO-1 expression levels were examined. Membranes were reprobed with β-actin to ensure equal loading across the samples. 
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RESULTS
AML resistance to cytarabine and daunorubicin.
To understand the mechanisms of chemoresistance 
in AML cells to cytarabine and daunorubicin, we have 
examined the levels of apoptosis of primary AML 
samples and AML cell lines in response to varying 
concentrations of these drugs. The drug concentrations 
selected were based on previous studies [26, 27]. One 
µM of cytarabine is a clinically achievable concentration 
obtained in situations where a standard dose of cytarabine 
is administered [28]. Table 1 shows the relevant clinical 
data for the AML patient samples tested in these studies. 
Figure 1A shows apoptosis for both AML samples and 
AML cell lines in response to both cytarabine (0.5 µM 
and 1 µM) and daunorubicin (0.2 µM and 0.5 µM) in 
concentration-dependent manners. Figure 1B shows 
that cytarabine (0.5 µM), daunorubicin (0.2 µM) or a 
combination of both cytarabine and daunorubicin induce 
cell death by apoptosis as measured by annexin-V and PI 
Figure 3: Silencing HO-1 increases AML cell apoptosis to cytarabine and daunorubicin (A) Flow cytometry was used 
to measure the transfection efficiency of the lentivirus based miRNA HO-1/GFP construct. (B) U937 and THP-1 cells were 
infected with a lentiviral based miRNA HO-1/GFP knockdown construct, whilst the control was infected with lentiviral based miRNA 
negative construct. RNA was extracted from each sample and HO-1 mRNA expression was measured using real-time PCR. (C)  Whole 
cell protein extracts were collected and separated via SDS-PAGE and examined using Western immunoblotting analysis to investigate 
HO-1 expression. (D) Both control U937 and THP-1 cells and HO-1 silenced U937 and THP-1 cells were treated with cytarabine 0.5 µM 
and daunorubicin 0.2 µM for 24 hours. Cells were stained with annexin-V and PI, the percentage of viable cells was measured via flow 
cytometry. 
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staining. What is clear from these findings is that there 
is a range of sensitivities to the chemotherapeutics and 
that there are significant levels of living cells that remain 
resistant to these cytotoxic agents, even in combination.
Cytarabine and daunorubicin induce HO-1 
expression in AML cells. 
Since we have previously shown that HO-1 protects 
AML cells from apoptotic stimuli, we wanted to determine 
if either cytarabine or daunorubicin could induce the 
expression of this cytoprotective gene in AML cells. 
Figure 2A shows that both cytarabine and daunorubicin 
induce HO-1 mRNA expression by 24 h of drug exposure 
in both AML cell lines and AML patient samples. Figure 
2B also reiterates the above point in AML cell lines and 
shows the effect on HO-1 mRNA expression of 24 h 
drug exposure to cytarabine and daunorubicin alone or 
in combination. Interestingly, HO-1 mRNA expression 
is increased further when the cells are exposed to both 
chemotherapeutic agents together. Figure 2C shows 
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Figure 4: Reactive oxygen species (ROS) modulate the apoptotic potential of cytarabine and daunorubicin in AML 
cells. (A) U937 and THP-1 cells were treated with cytarabine 0.5 µM and daunorubicin 0.2 µM for up to 6 hours and then washed with PBS 
and incubated for 15 minutes with 10 µM of H2DCFDA. ROS production in response to drug exposure was examined using flow cytometry. 
(B) U937 and THP-1 cells were treated with cytarabine 0.5 µM and daunorubicin 0.2 µM for 24 hours with or without pre treatment with 
NAC (10 µM for daunorubicin treated cells and 5 µM for cytarabine treated cells) for 30 minutes. Cells were stained with annexin-V and 
PI, their response to NAC was examined using flow cytometry. (C) U937 and THP-1 cells were treated with either cytarabine 0.5 µM and 
NAC 5 µM or daunorubicin 0.2 µM and NAC 10µM for 24 hours. RNA was extracted and mRNA HO-1 expression was measured using 
real- time PCR.Oncotarget 2011; 2:  658 - 668 664 www.impactjournals.com/oncotarget
a Western blot indicating that HO-1 protein was also 
induced by both cytarabine and daunorubicin after 24 h 
drug exposure. Thus these front-line chemotherapeutic 
agents are able to readily induce HO-1 in AML cells. 
Furthermore, at the concentrations used, daunorubicin is 
somewhat better at killing off U937 cells than is cytarabine 
(Figure 1), with daunorubicin only weakly inducing 
HO-1 in U937 cells compared to cytarabine’s induction 
(Figure 2C). This correlates perfectly with a role for HO-1 
induction in drug-resistance in U937 cells. Likewise, it is 
notable that both agents can equally induce strong HO-1 
expression in THP-1 cells, with a similar inability towards 
efficient cytotoxicity in those cells.
Silencing HO-1 increases AML cell apoptosis to 
cytarabine and daunorubicin.
We developed a lentivirus-based miRNA delivery 
system on a GFP backbone to target HO-1 mRNA 
knockdown and silence HO-1 expression in AML cells. 
Figure 3A shows that we can achieve > 95% transfection 
efficiency  as  measured  by  flow  cytometry.  Figure  3B 
shows that HO-1 mRNA expression in both THP-1 and 
U937 control and HO-1-silenced cells, with greater 
than 95% knock-down of endogenous HO-1 mRNA 
levels observed. Figure 3B also indicates HO-1 protein 
expression in THP-1 control and HO-1-silenced cells, with 
almost no detectable levels of HO-1 observed specifically 
with the HO-1 miRNA lentivirus. Next we wanted to 
determine if either cytarabine or daunorubicin induced 
HO-1 expression could protect AML cells from apoptosis. 
To do this we used lentiviral-based miRNA HO-1 
knockdown cells (compared to control negative miRNA 
lentiviral knockdown cells) treated with either cytarabine 
or daunorubicin for 24 h. Figure 3Cand 3D show the 
apoptotic responses of control- and HO-1-silenced THP-1 
and U937 cells after treatment with either cytarabine or 
daunorubicin. The HO-1-silenced THP-1 and U937 cells 
were more susceptible to apoptosis compared to the non-
silenced cells. These findings indicate that HO-1 is playing 
a part in cellular protection mechanisms observed in 
apoptosis-resistance towards cytarabine or daunorubicin.
ROS modulates the apoptotic potential of 
cytarabine and daunorubicin in AML cells. 
We have previously shown in AML cells that 
H2DCFDA oxidation occurs in response to the proteasome 
inhibitor  bortezomib  and  also  in  response  to  NF-ĸB 
inhibitor BAY 11-7082 [29, 30]. We have also shown 
that  ROS  induced  by  these  drugs  are  responsible  for 
upregulating HO-1 expression. Here we wanted to 
determine if cytarabine and daunorubicin increased 
HO-1 expression through a ROS-dependent mechanism. 
Figure 4A shows H2DCFDA oxidation in U937 and 
THP-1 cells in response to cytarabine and daunorubicin 
treatment over a 6 h time period. N-acetylcysteine (NAC) 
is an antioxidant scavenger which quenches ROS activity 
present within the cellular environment. NAC was used 
to determine if removing ROS would block cytarabine- 
and daunorubicin-induced HO-1 expression. Finally, we 
wanted to determine whether NAC could block apoptosis 
induced by cytarabine and daunorubicin. Figure 4B show 
that NAC effectively inhibits apoptosis in cytarabine- 
and daunorubicin-treated THP-1 and U937 cells, thus 
demonstrating that ROS are responsible for cytarabine- 
or daunorubicin-induced cell death of AML cells. Figure 
4C shows a decrease in mRNA HO-1 expression in the 
presence of NAC compared to that of the control, further 
implicating  ROS  in  the  chemotherapeutic-induction  of 
HO-1 and its consequent cytoprotection observed in AML. 
DISCUSSION
In this study we have investigated the role of HO-1 
in protecting AML cells from apoptosis in response 
to cytarabine and daunorubicin. We have previously 
shown that HO-1 can protect AML cells from apoptosis 
in response to the proteosome inhibitor, bortezomib and 
the NF-κB inhibitor, BAY11-7082 [29, 30]. In the present 
work, we show that expression of HO-1 is induced in 
response to cytarabine, daunorubicin and a combination 
of both agents. Interestingly HO-1 mRNA expression 
is increased further when the cells are treated with a 
combination of the drugs which one would expect because 
of the presence of both agents acting via differing modes 
of action to induce apoptosis. Referring to Figure 1B, 
oddly the percentage of viable cells present within the 
sample population is actually between that of separate 
cytarabine and daunorubicin exposure. Furthermore 
silencing HO-1 expression in combination with either 
cytarabine or daunorubicin induces a greater apoptotic 
response in AML cells. Finally we show that both 
cytarabine and daunorubicin cause AML cells to generate 
ROS production and this in turn induces HO-1 expression, 
which  subsequently  reinforces  any  cellular  resistance 
towards these drugs. A prior report has already shown 
ROS production in the presence of cytarabine in U937 
cells [26]. These results provide novel insight into the role 
of HO-1 in protecting human AML cells from cytarabine 
and daunorubicin.
In a broad range of morphologic and cytogenetic 
subtypes of primary human AML cells and human AML 
cell lines, both cytarabine and daunorubicin consistently 
induce HO-1 expression by 24 h. We also examined the 
effects of daunorubicin and cytarabine on HO-1 expression 
at earlier time points finding no increase in HO-1 mRNA 
levels (not shown). This time lag between addition of 
drug and HO-1 induction in AML cells is interesting. We 
hypothesise that this is likely to be due to the complex 
nature of the HO-1 promoter and its regulation. Nuhn et Oncotarget 2011; 2:  658 - 668 665 www.impactjournals.com/oncotarget
al have reported that HO-1 expression is usually increased 
in human cancer cells and is also increased further by the 
addition of cytotoxic agents [31]. Subsequent silencing 
of HO-1 in these AML cell lines significantly decreases 
the percentage of viable AML cells present within the 
population treated with fixed doses of either cytarabine 
or daunorubicin. Therefore we suggest inhibiting 
HO-1 could potentially enhance AML cell response to 
these chemotherapeutic agents in vivo. Fang et al have 
determined the presence of a HO-1 inhibitor in vivo can 
enhance tumour responsiveness to chemotherapeutic 
agents [32]. 
Protection from apoptosis conferred to AML cells by 
HO-1 in the current study appears to be medicated through 
regulation  of  ROS  produced  in  response  to  cytarabine 
and daunorubicin exposure. With regards to HO-1 and its 
ability to protect cells from undergoing apoptosis, there 
are a number of different proposed mechanisms. The 
first is by decreasing the levels of the pro-oxidant, haem 
[32, 33]; the second, by increasing the concentration of 
bilirubin, an antioxidant [32]; and the final mechanism is 
by increasing the levels of carbon monoxide, curiously 
generally thought to be an anti-apoptotic molecule [13, 
34, 35]. Together, these mechanisms act either alone or 
in a combined way to protect cancer cells from apoptosis. 
What is intriguing about AML cells is that they seem to 
have evolved to manipulate this pathway to provide it 
with a growth advantage over normal non-cancerous 
control cells. AML (or any cancerous cell) probably 
doesn’t set out to be drug-resistant, but there is a varying 
population of cancer stem cells that are relatively able 
to cope with any cytotoxic insult they receive from 
cytarabine or daunorubicin. We show here that these 
resistance mechanisms heavily involve HO-1. A patient’s 
HO-1 response to chemotherapeutics will go a long way 
in determining their clinical outcome.
In our previous study we showed that basal levels of 
HO-1 are low compared to normal cells and that NF-κB 
activation reduced basal HO-1 expression. Furthermore, 
Nrf-2 activation could override this regulation [29]. In 
fact any number of transcription factors can regulate HO-1 
expression [24, 25]. In this study we concentrated on the 
role of HO-1 expression in regulating chemotherapy-
induced apoptosis but cannot preclude the involvement of 
other transcriptional elements.
In summary we report that silencing HO-1 
significantly increases in vitro sensitivity of AML cells to 
cytarabine and daunorubicin, two front-line chemotherapy 
agents currently widely used to treat this type of leukaemia. 
Previously we have shown that HO-1 plays an important 
role in protecting AML cells from apoptotic stimuli and 
here we propose that this is likely to be clinically relevant 
and thus HO-1 warrants further investigation as a target in 
future therapeutic strategies. 
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MATERIALS AND METHODS
Materials
The AML-derived cell lines THP-1 and U937, were 
obtained from the European Collection of Cell Cultures, 
where cell identity is confirmed by cytogenetic analuysis. 
Cells were used in the laboratory for a maximum of 6 
months post-revival from liquid nitrogen storage, to ensure 
integrity and retention of characteristics. Anti-human 
HO-1  antibody  was  purchased  from  R  &  D  Systems 
(Abingdon, UK). All other antibodies were obtained from 
Abcam  (Cambridge,  UK). All  primers  were  purchased 
from  Invitrogen  (Paisley,  UK).  Micro  RNA  (miRNA) 
vector was cloned on site. Annexin-V and propidium 
iodide (PI) were purchased from Abcam (Cambridge, 
UK). Cytarabine (dissolved in water, stored at -20 ºC as 
a 4.1 mM stock) and daunorubicin (dissolved in water, 
stored at -20 ºC as a 0.95 mM stock) were both purchased 
from Sigma-Aldrich (St Louis, MO). All other reagents 
were purchased from Sigma- Aldrich unless stated. 
Cell Culture
Primary AML cells were obtained under local 
ethical approval (LREC ref 07/H0310/146). For primary 
cell isolation, heparinised blood was collected from 
volunteers and  isolated by  Histopaque (Sigma-Aldrich, 
St  Louis,  MO)  density  gradient  centrifugation.  U937 
were cultured in a humidified atmosphere at 37ºC with 
5% CO2  in  RPMI-1640  from  Invitrogen  (Paisley,  UK) 
supplemented  with  10%  foetal  bovine  serum  (FBS)
(Biosera, UK) and 1% L-glutamine incubated. 293FT cells 
were obtained from Invitrogen and were grown in DMEM 
high glucose (Invitrogen) supplemented with 10% FBS, 6 
mM L-glutamine, 0.1 mM non-essential amino acids and 
1 mM sodium pyruvate.
RNA extraction and real-time PCR
Total RNA was extracted from 1 x 106 cells using RNA 
lysis solution and a nucleic acid Prepstation both purchased Oncotarget 2011; 2:  658 - 668 666 www.impactjournals.com/oncotarget
from  Applied  Biosystems  (Warrington,  UK)  following 
the manufactures instructions. Applied Biosystems RNA 
PCR core kit was used for reverse transcription. SYBR 
green technology (Roche) was used on cDNA produced 
via  the  reverse  transcription  of  purified  RNA.  After 
pre-amplification (95 ºC for 2 min) the reactions were 
amplified for 45 cycles (95ºC for 15 s, then 60ºC for 10 s, 
followed by 72ºC for 10 s) on a Lightcycler 480 (Roche) as 
described [29]. HO-1 mRNA expression was standardised 
against GAPDH expression using the standard curve 
analysis method. Primer sequences were: GAPDH forward 
5’-ACCAGCCTCAAGATCATCAGC-3’; GAPDH 
reverse 5’-TGCTAAGCAGTTGGTGGTGC-3’; HO-1 
forward 5’-ATGGCCTC CCTGTACCACATC-3’ and 
HO-1 reverse 5’-TGTTGCGCTCAATCTCCTCCT-3’. 
Western immunoblotting
Total protein was extracted from 1 x 106 cells 
using radioimmunoprecipitation assay (RIPA) buffer as 
described [29]. Protein was transferred onto nitrocellulose 
membrane, probed according to the antibody 
manufacturer’s guidelines and then examined using 
enhanced chemiluminescence (ECL) detection in a Li-Cor 
Odyssey IR imaging system. 
Flow Cytometry
Flow cytometry for measuring apoptosis was 
performed  on  an Accuri  C6  flow  cytometer  (Accurri). 
Samples were collected, centrifuged at 500 x g, 5 min 
then resupended and stained with Annexin-V and PI 
dye, followed by detection. N-acetylcysteine (NAC) 
antioxidant  ROS-scavanger  was  used  to  assess  the 
presence of ROS, whereby cells were treated with NAC 
with relevant chemotherapeutic agent for 24 h, prior to 
sample flow cytometry analysis. 
Dichlorofluorescein Assay
A  dichlorofluorescein  (DCF)  assay  was  used  to 
determine  cellular  ROS  generation  [21].  Cells  were 
washed  with  PBS  and  then  incubated  with  10  µM  of 
2’,7-dichlorodihydrofluorescein  diacetate  (H2DCFDA) 
for 15 min at 37 ºC and 5% CO2. Flow cytometry was 
used to measure the fluorescence intensity of H2DCFDA. 
The  mean  channel  fluorescence  of  a  treated  sample  is 
divided by that of the control and then multiplied by 100, 
thus obtaining the relative percentage change. The relative 
fluorescence intensity of H2DCFDA detected represents 
the steady state of ROS generation [21, 36, 37]. 
Virus construction and infection
MicroRNA (miRNA) sequence miRNA-HO-1-166 
(5’-TCCTCATGAACTCAGCATTCT-3’) targeting 
human HO-1 was selected with Invitrogen Block-iT 
RNAi designer software (www.invitrogen.com/rnai). 
pcDNATM6.2-GW/EmGFP-miR-neg  plasmid  from 
Invitrogen was used as a source for negative control miRNA 
expression. miRNA-encoding viruses were produced with 
Block-iT Lentiviral Pol II miRNAi expression system 
(Invitrogen) in 293FT cells. Lentiviral stocks were 
concentrated using Lenti-XTM concentrator and titers 
were determined with Lenti-XTM  qRT-PCR  titration  kit 
(both purchased from Clontech, Saint-Germain-en-Laye, 
France). For infection, cells were plated onto 12 well 
plates at 2.5 x 105 cells/well and infected with lentiviral 
stocks at an MOI of 10 in the presence of polybrene, then 
analysed by flow cytometry, RT-PCR and Western blotting 
48 h post infection. Stably transduced cells were selected 
using Blasticidin selection marker (8 μg/ml) for 2 weeks 
before use. 
STATISTICAL ANALYSES
Student’s  T-test  was  used  to  assess  the  statistical 
significance compared to that of the control values. Results 
with a P < 0.05 were considered statistically significant 
and  are  indicated  (*).  Values  represent  the  means  ± 
SEMs from at least three independent experiments, or of 
representative blots/plots that are typical of at least three 
independent findings.
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